Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland
Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland
复制标题
DOI：
10.1016/j.ijantimicag.2020.106019
复制
发表时间：
2020-07-01
影响因子：
10.8
通讯作者：
Mancini, Stefano
中科院分区：
文献类型：
--
作者：
Bodendoerfer, Elias;Marchesi, Martina;Mancini, Stefano
在2014年在瑞士大苏黎世地区收集的3358株连续大肠埃希菌临床分离株中评估了氨基糖苷类和β-内酰胺类耐药的同时发生。在470/3358 E中观察到对至少一种检测的氨基糖苷类药物不敏感。大肠埃希菌（14%）。在广谱β-内酰胺酶（BSBL）产生菌（1241/3358株）、超广谱β-内酰胺酶（ESBL）产生菌（262/3358株）和AmpC产生菌（66/3358株）中，分别有23%、52%和20%的菌株对氨基糖苷类抗生素耐药。相反，氨基糖苷类敏感菌株很少对β-内酰胺类耐药（33/1777，1.9%）。对439株氨基糖苷类耐药大肠杆菌的基因组进行了分析。大肠杆菌进行测序，并分析氨基糖苷类和β-内酰胺类基因型。最常见的氨基糖苷类耐药基因为aph（3 '）-Ia（133株，30.3%）、aac（3）-IId（100株，22.8%）和aac（6'）-Ib-cr（52株，11.8%）。与β-内酰胺耐药基因最常见的关联是aph（3 '）-Ia或aac（3）-IId与bla TEM-1（分别为94和72株），以及aac（3）-IIa/aac（6'）-Ib-cr与bla CTX-M-15 /bla OXA-1（23株）。这些结果表明aac（3）和aph（3 '）基因型与BSBL的产生频繁相关，而aac（6'）基因型与ESBL的产生频繁共存。在联合治疗中，必须考虑氨基糖苷类耐药和β-内酰胺酶产生的高并发率。(c)2020年，任作家。由Elsevier B. V.发布，这是CC BY许可下的开放获取文章。(http：//creativecommons.org/licenses/by/4.0/）
The co-occurrence of aminoglycoside and beta-lactam resistance was assessed in 3358 consecutive Escherichia coli clinical isolates collected in 2014 in the greater Zurich area, Switzerland. Non-susceptibility to at least one of the tested aminoglycosides was observed in 470/3358 E. coli strains (14%). In strains categorized as broad-spectrum beta-lactamase (BSBL)-producers (1241/3358 isolates), extended-spectrum beta-lactamase (ESBL)-producers (262/3358) and AmpC-producers (66/3358), resistance to aminoglycoside was found in 23%, 52% and 20% of the isolates, respectively. In contrast, aminoglycoside-susceptible strains were rarely resistant to beta-lactams (33/1777, 1.9%). The genomes of 439 aminoglycoside-resistant E. coli were sequenced and aminoglycoside and beta-lactam genotypes were analysed. The most prevalent aminoglycoside resistance genes were aph(3')-Ia (133 strains, 30.3%), aac(3)-IId (100 strains, 22.8%), and aac(6')-Ib-cr (52 strains, 11.8%). The most frequent associations with beta-lactam resistance genes were aph(3')-Ia or aac(3)-IId with bla TEM-1 (94 and 72 strains, respectively), and aac(3)-IIa/aac(6')-Ib-cr with bla CTX-M-15 /bla OXA-1 (23 strains). These results indicate a frequent association of aac(3) and aph(3') genotypes with BSBL production, and a frequent co-occurrence of aac(6') genes with ESBL production. The high rate of co-occurrence of aminoglycoside resistance and beta-lactamase production must be considered in combination therapy. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)